HS
ELVN icon

HighVista Strategies’s Enliven Therapeutics ELVN Stock Holding History

HighVista Strategies’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Sell
73,102
-9,434
-11% -$261K 0.79% 41
2025
Q4 		$1.27M Sell
82,536
-176,599
-68% -$3.52M 0.33% 83
2025
Q3 		$5.3M Buy
259,135
+117,619
+83% +$2.37M 1.3% 18
2025
Q2 		$2.84M Buy
141,516
+29,057
+26% +$550K 1.04% 21
2025
Q1 		$2.21M Hold
112,459
– – 0.85% 28
2024
Q4 		$2.53M Hold
112,459
– – 0.94% 26
2024
Q3 		$2.87M Sell
112,459
-7,330
-6% -$170K 0.99% 32
2024
Q2 		$2.8M Sell
119,789
-7,065
-6% -$149K 1.02% 26
2024
Q1 		$2.23M Sell
126,854
-10,387
-8% -$159K 0.8% 43
2023
Q4 		$1.9M Buy
137,241
+12,654
+10% +$155K 0.69% 48
2023
Q3 		$1.7M Buy
124,587
+3,514
+3% +$59.2K 0.79% 39
2023
Q2 		$2.47M Buy
+121,073
New +$2.45M 1.13% 30

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HighVista Strategies's ELVN Position: Q1 2026 in Review

HighVista Strategies reduced its Enliven Therapeutics (ELVN) stake by 11% in Q1 2026, selling an estimated $261K and leaving 73,102 shares worth $2.87M. The position accounts for 0.79% of the portfolio, ranked #41.

HighVista Strategies first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. The position peaked at $5.3M in Q3 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • HighVista Strategies held 73,102 shares of Enliven Therapeutics worth $2.87M as of Q1 2026.
  • HighVista Strategies sold 9,434 Enliven Therapeutics shares in Q1 2026, an estimated $261K.
  • Enliven Therapeutics made up 0.79% of HighVista Strategies's portfolio in Q1 2026, its #41 holding.
  • HighVista Strategies first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • HighVista Strategies's Enliven Therapeutics position peaked at $5.3M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.